Objective. To investigate the effect of TNF inhibitors (TNFis) on incidental and progressive hand OA in recent-onset RA patients after a 10 year follow-up.
Introduction
Hand OA is a prevalent form of OA and is associated with a lower health-related quality of life [1] . Radiographically, OA is characterized by osteophyte formation and joint space narrowing [2] . Although research in OA has increased in recent years, the pathogenesis of OA remains incompletely understood [3] . However, there is increasing evidence that local and systemic inflammation are involved in its development [4] . In patients with hand OA, inflammatory features in hand joints seen on US, such as a positive power Doppler signal and synovial hypertrophy, are associated with progression of joint damage and pain [5, 6] . In addition, synovitis evident on MRI is associated with radiological onset and progression of hand OA in a doseresponse manner [7, 8] .
The inflammatory process seen in hand OA may be mediated by the production of pro-inflammatory cytokines by the synovium [9] . An important pro-inflammatory cytokine involved in OA is TNF-a [4, 10] . TNF-a inhibitors have proven to be an effective treatment in other inflammatory rheumatic conditions, such as RA [11, 12] . This raises the question whether TNF-a inhibitors could be a new treatment strategy for hand OA. However, previous research regarding TNF-a inhibitors in patients with hand OA is limited and thus far results are inconclusive [13, 14] . OA is a slowly progressive condition warranting a long study duration to evaluate radiographic damage, which may explain the inconclusive results in previous short-term trials.
A study investigating the effect of the TNF-a inhibitor infliximab on hand OA after 3 years of follow-up in RA patients suggested an inhibitory effect on osteophyte formation [15] . In contrast to OA, RA is not typically characterized by osteophytes. However, joints of RA patients may show bone remodelling and osteophytes, often referred to as secondary OA [16] , which might be due to an imbalance between bone resorption and formation [16, 17] . In addition, since hand OA is a prevalent condition with increasing prevalence in older age, primary hand OA is likely to co-occur in RA patients. Involvement of DIP joints in RA has been described with varying prevalences [18, 19] but is generally deemed to occur infrequently [20] . In contrast, OA typically affects the DIP joints [21] . Therefore, although a strict distinction cannot be made, OA in the DIP joints will mostly represent primary OA, while OA in the PIP joints could be either primary or secondary OA. We utilized a study with 10 years of follow-up of recent-onset RA patients, which enabled us to study the long-term effects of TNF-a inhibitor treatment on incidental and progressive radiographic hand OA.
Methods

Patients and study design
The current study is an observational longitudinal study analysing 10 year follow-up data from the BeSt study, Dutch acronym for Behandel Strategie € en, i.e. treatment strategies. The BeSt study is a randomized clinical trial designed to compare the efficacy of four treatment strategies in recent-onset RA patients. The study was conducted by rheumatologists participating in the Foundation for Applied Rheumatology Research in 18 peripheral and 2 university hospitals in The Netherlands. Between April 2000 and August 2002, 508 recent-onset RA patients were included. Study details have previously been described [12] . The BeSt study protocol was approved by the medical ethics committee at each participating hospital and all patients gave written informed consent prior to inclusion; no additional approval was required for this analysis. Patients were initially randomized to one of the four treatment strategies, stratified by centre: sequential monotherapy (strategy 1); step-up combination therapy (strategy 2); initial combination therapy with MTX, SSZ and prednisone (strategy 3) and initial combination therapy with MTX and infliximab (strategy 4).
Interventions and follow-up
Treatment adjustments were made according to a standardized protocol [12] . Every 3 months the DAS [22] was assessed to determine treatment response. Low disease activity, expressed as a DAS 42.4, was the primary treatment goal of the BeSt study protocol. A DAS >2.4 indicated the need to intensify treatment, which involved a change in medication or dosage according to the treatment protocol, as previously described [12] . Due to these treatment adjustments, patients in strategy arms 13 could be treated with infliximab (and in some cases a subsequent other TNF-a inhibitor) as delayed treatment after failing on at least three previous DMARDs. These patients, and patients in strategy arm 4 (initial infliximab), were compared with patients who never required treatment adjustment to a TNF-a inhibitor during the 10 year follow-up period. Treatment dosage was tapered to a maintenance dose if DAS was 42.4 for 56 months. In case of a continuous DAS <1.6, treatment was tapered to nil.
Radiographic assessment of hand OA Conventional radiographs of both hands were obtained annually. Only patients with available hand radiographs at baseline and the 10 year follow-up were included in the current study. For both hands the DIP, PIP and first IP joints were scored for osteophytes using the Osteoarthritis Research Society International (OARSI) atlas on a scale of 03 per joint [23] and according to the KellgrenLawrence (KL) scoring method on a scale of 04 per joint [24] . Summation of scores resulted in scales of 054 and 072 per patient for the OARSI osteophyte score and the KL score, respectively. Radiographs were scored by one reader (M.L.), paired, in known time order, but blinded for treatment and patient characteristics. An intraclass correlation coefficient was calculated on a random sample of 10% of pairs of hand radiographs to evaluate intrareader reliability. The intraclass correlation coefficients for osteophytes and KL were 0.78 and 0.83, respectively. Subsequently the smallest detectable difference (SDD) and smallest detectable change (SDC) were calculated to determine the cutoff for incidental OA and progressive OA, respectively [25] . The SDD and SDC for the osteophyte score and KL were 0.70 and 2.25 and 0.80 and 2.76, respectively. Two definitions of incidental OA and progressive OA were used, based on the osteophyte score and KL score, respectively.
Using OARSI osteophyte scoring, OA at baseline was defined as an osteophyte summation score of at least 1. At the patient level, incidental OA and progressive OA were defined as an increase in total osteophyte score 5SDD (= 1) and 5SDC (= 3), respectively, over 10 years. At the joint level, progressive OA was defined as an increase in osteophyte score 51 in one joint over 10 years independent of the presence of OA at baseline. Using KL scoring, OA at baseline was defined as a KL summation score at baseline of at least 2. At the patient level, incidental OA and progressive OA were defined as an increase in the total KL score 5SDD (= 1) and 5SDC (= 3), respectively, over 10 years. At the joint level, progressive OA was defined as an increase in the KL score 51 in one joint over 10 years independent of the presence of OA at baseline.
Statistical analysis
As a consequence of the long follow-up duration, some patients were no longer willing to participate on a 3 month interval. In order to prevent dropout, these patients were followed on a yearly basis when possible, leading to missing data of the quartile visits. To allow analysis of TNF-a inhibitor treatment duration, missing data of in-between visits were imputed using last observation carried forward. Patients could have used the TNF-a inhibitor infliximab as a result of the initial randomization strategy or used other TNF-a inhibitors after completing all steps of the treatment protocol [12] . Analyses were performed for all possibly used TNF-a inhibitors combined. The association between TNF-a inhibitors and incidental and progressive OA was analysed by multivariate regression analysis.
On the patient level, a significant interaction was observed between treatment duration and OA presence at baseline. Therefore, analyses were stratified on the presence of OA at baseline to determine separate associations between TNF-a inhibitor treatment duration on incidental OA in the subgroup of patients without OA at baseline and progressive hand OA in the subgroup of patients with OA at baseline. No relevant interaction between TNF-a inhibitor treatment duration and OA at baseline was observed on the joint level, therefore these analyses were not stratified on OA presence at baseline.
All analyses were stratified by joint group, resulting in DIP and PIP joint groups, of which the latter included the PIP joints and first IPJ. The effect of TNF-a inhibitor treatment duration on incidental and progressive OA on the patient level was analysed using generalized linear models with Poisson distribution and robust standard errors to obtain relative risks (RRs) [26] . To further explore the effect of TNF-a inhibitors on hand OA, analyses on the joint level were performed using generalized estimating equations to allow correction for intrapatient variability. An exchangeable correlation structure, log link function and Poisson distribution with robust standard errors were used to obtain RRs [26] . To allow comparison of the scoring methods, all analyses were performed for the OA definitions based on OARSI osteophyte score and KL score separately.
Possible confounders were identified using univariable regression analysis using generalized linear models with Poisson distribution and robust standard errors. All analyses were adjusted for age, gender, time-averaged DAS and time-averaged modified Sharpvan der Heijde score [27] of the hands. In addition, progressive OA analyses on the patient level were also adjusted for the baseline OA score. Data analysis was performed using SPSS version 23 (IBM, Armonk, NY, USA).
Results
Patient characteristics
Of the initial 508 RA patients, 262 patients were available for assessment of hand radiographs at baseline and after 10 years of follow-up. The initial BeSt study population was significantly older compared with the current study population, with a mean age of 54 years, and had a slightly higher mean HAQ score and DAS of 1.4 and 4.4, respectively. Baseline demographic and disease-related characteristics of the current patient population are shown in Table 1 . At baseline the mean age was 52 years and 66% of patients was female. The mean RA disease activity was high, with a DAS of 4.3. Using the OARSI osteophyte score, OA at baseline in any IP joint was present in 55% of patients (39% of women and 16% of men). The group with OA at baseline was significantly older, with a mean age of 57 years, compared with the group without OA at baseline (46 years). OA occurred more often in the DIP joints (48%) rather than the PIP joints (31%). The patients treated with TNF-a inhibitors were significantly younger and a significantly higher percentage was RF positive and anti-CCP positive compared with patients who never received TNF-a inhibitor treatment.
Distribution and change of OA scores over 10 years
The hand radiographs of one patient were not assessable due to poor quality of the radiographs, therefore 261 patient radiographs were scored. Based on the osteophyte score, incidental OA occurred in 56 patients (47%) in any IP joint. Of the 143 patients with OA at baseline, progressive OA was present in 78 patients (55%) in any IP joint (Table 2) . Using the KL scoring method, 68 patients (46%) developed incidental OA in any IP joint. Progressive OA was present in 82 patients (71%) in any IP joint (Table 3) .
TNF-a inhibitors are associated with a lower RR on OA progression in DIP joints
Of patients with and without hand OA at baseline, irrespective of joint location, 63% and 55% were treated with TNF-a inhibitors with a median treatment duration of 47 and 36 months, respectively. Multivariate analysis showed no associations between the duration of TNF-a inhibitor treatment and incidental OA defined by the OARSI osteophyte score (Table 4 ). In contrast, every month of TNF-a inhibitor treatment significantly lowered the RR [0.987 (95% CI 0.978, 0.996), P = 0.003] for progressive OA in the DIP joints. This effect was not seen for any IP joints together or for the PIP joints separately (Table 5 ). The independent contributions of the other variables included in the analysis can be found in supplementary Table A, available at Rheumatology online. The analyses with OA defined using the KL method showed comparable results.
As shown in Table 6 , the analyses on the joint and patient levels were comparable. The inhibitory effect of TNF-a inhibitors on OA progression, defined by the OARSI osteophyte score, was observed both in all IP joints [RR 0.996 (95% CI 0.993, 1.000); P = 0.05] and the DIP joints separately [RR 0.996 (95% CI 0.991, 1.000), P = 0.048]. The analyses using OA defined with the KL method showed similar results.
The effect of TNF-a inhibitors on progressive OA is independent of prednisone A sensitivity analysis was performed in the patients that were never treated with prednisone during the 10 year follow-up. Similar to the main analyses, in patients that never received prednisone treatment, prolonged TNF-a inhibitor treatment was associated with a reduced risk of OA progression in the DIP joints [RR 0.978 (95% CI 0.961, 0.995), P = 0.012] but not in the PIP joints.
Discussion
Ten years of clinical and radiographic follow-up in the BeSt study offered the unique opportunity to study the long-term effects of TNF-a inhibitors on the development and progression of hand OA. In patients with radiographic hand OA at baseline, TNF-a inhibitor treatment was associated with a reduced risk of OA progression in the DIP joints for each month of treatment. This effect was still present in patients without prednisone use, with larger risk reductions in patients that did not receive prednisone treatment. This suggests that TNF-a inhibitor treatment has an inhibitory effect on the progression of OA at the joint level and a potential effect on the prevention of OA development in other DIP joints in that particular patient. This is comparable to previous research showing that OA patients are not only at risk for OA progression in the affected joints, but for development of incidental OA in joints without previous damage [28] . In contrast to the effect on hand OA progression, we found no effect of TNF-a inhibitor treatment duration on the development of incidental hand OA. It is possible that the factors that are of importance in the development of incidental hand OA, such as mechanical factors, are different from those important in OA progression, for example, synovitis [7, 8] . Another potential explanation may be the different cut-off values that were used to define incidental and progressive hand OA.
The current study has a long follow-up duration, which is important in studying radiographic damage in a slowly progressive condition such as OA. This allowed us to look at the effect of long-term treatment duration of different TNF-a inhibitors combined. To date, studies investigating the effects of TNF-a-inhibiting medication on hand OA have been rare, inconclusive and have investigated either other primary outcomes or a different subpopulation of OA patients [13, 14] . To our knowledge, we are the first to look at the effect of duration of TNF-a-inhibiting treatment on hand OA after such a long follow-up duration. GulerYuksel et al. [15] , investigating the effect of infliximab on secondary hand OA after 3 years of follow-up in the BeSt study, suggested a role for infliximab in the progression of secondary hand OA. Comparable to our findings, they found a protective effect of infliximab on OA in the DIP joints and no association between inflammation and OA in the PIP joints. However, possibly due to the relatively short followup, no statistically significant differences were observed.
The observed differences in treatment effect on OA in DIP and PIP joints are difficult to interpret. In light of the studied population consisting of RA patients, OA in these two joint categories may represent two distinct disease entities. RA disease activity, likely due to increased TNF levels, is associated with altered bone remodelling that favours bone resorption due to promotion of osteoclastogenesis and inhibition of osteoblast differentiation [29] . Disease remission may reverse osteoblast inhibition, halting erosion progression, and might even lead to erosion One patient missing due to poor quality of hand radiographs at 10 years.
https://academic.oup.com/rheumatology repair. Evidence for repair in RA patients is scarce [30] . Studies investigating this phenomenon show that when present, repair is limited, it only occurs in joints with severe erosions and it mainly involves bone attrition at the base of the erosion [31, 32] . One could argue that altered tissue repair might also lead to secondary OA, therefore most likely occurring in the joints most severely affected by RA activity, such as the PIP joints. It is reasonable that the underlying pathophysiological mechanisms of primary and secondary OA are different, which may explain the observed differences in treatment effect in these joint groups. Another explanation could be that the radiographic evaluation of secondary OA is more complicated and less sensitive, since structural damage through different processes can co-occur. More research is necessary to test these hypotheses and to establish in which step of the OA process TNF-a inhibitors interfere. Although our study has considerable strengths, such as the long follow-up duration of 10 years and a welldescribed patient cohort, it also has limitations. This study was a randomized trial primarily designed to investigate targeted treatment in RA patients, which makes generalizations less straightforward. The prevalence of primary hand OA in early RA patients might not be directly comparable to the general population. In addition, this population made it more challenging to determine the presence of hand OA, due to the combined presence of OA and RA deformations. Compared with other hand OA studies, we found a relatively high prevalence of OA in the PIP joints [28, 33] . As RA activity might influence the development of secondary OA [16] , the co-occurrence of secondary OA very likely explains the relatively high prevalence of OA in the PIP joints. It is important to realize that the methods used to define radiographic OA are not primarily designed to assess secondary OA and might therefore be better suited for assessment of primary OA. Furthermore, all radiographs were scored by a single reader. However, we have shown good intrareader reliability.
Another possible limitation of this study is the relatively high SDC, and therefore a quite strict cut-off for progressive hand OA, resulting from a rather sensitive reading of the hand radiographs. However, it is to be expected that if this influenced our data in any way, it will give an underestimation of the effect we have shown. Another potential cause of underestimation might come from selection bias. A long follow-up period often leads to missing data, which likely is not missing completely at random. In the current study we chose to analyse only the data from patients for whom hand radiographs at the 10 year followup were available. This might induce bias by study completion, leading to a selection of patients in a way comparable to survival of the fittest. Patients who do well on the study medication might be less likely to be lost to follow-up. This could select patients with less inflammation, so an effect of TNF-a-inhibiting medication may be less evident. In addition, in our patient selection there is missing data for patients that were seen at a yearly instead of a 3 month interval. In order to correct for this, we imputed missing data of infliximab use of the missing in-between visits to allow treatment duration analyses. Although multiple imputation is commonly believed to provide more robust and reliable models, a great number of unregistered factors were involved in the probability of receiving infliximab treatment, such as doctor preference or institutional guidelines. Therefore we used the last observation carried forward method, as this best fit our data.
In conclusion, we have shown that in recent-onset RA patients TNF-a inhibitor treatment is associated with a significantly reduced RR of radiographic hand OA progression in the DIP joints but not the PIP joints after 10 years. Although the effect sizes are small, these results provide evidence for influence of TNF-a in hand OA pathogenesis.
